Pharmacy Rebates. Based on an analysis of CY 2017 annual cost report data, retail pharmacy expenditures were reduced by supplemental rebates assumed to be collected by the MCPs. We reviewed CY 2017 historical experience period to assess a reasonably attainable level of supplemental pharmacy rebates. No adjustment for pharmacy rebates was made to the MAT therapeutic class due to ODM’s efforts to standardize drug dispensing for this therapeutic class. Supplemental rebates are assumed to vary by population from approximately 3.0% to 6.0% of total pharmacy expenditures.
Appears in 2 contracts
Samples: Ohio Medical Assistance Provider Agreement for Managed Care Plan, Ohio Medical Assistance Provider Agreement for Managed Care Plan
Pharmacy Rebates. Based on an analysis of CY 2017 2016 annual cost report data, retail pharmacy expenditures were reduced by supplemental rebates assumed to be collected by the MCPsrebates. We reviewed CY 2017 2016 historical experience period to assess a reasonably attainable level of supplemental pharmacy rebates. No adjustment for pharmacy rebates was made to For the MAT therapeutic class due to ODM’s efforts to standardize drug dispensing for this therapeutic classAFK population, we assumed an amount of Pharmacy Rebates consistent with the CFC and ABD child populations. Supplemental In aggregate, supplemental rebates are assumed to vary by population from be approximately 3.05.0% to 6.05.5% of total pharmacy expenditures.
Appears in 2 contracts
Samples: Ohio Medical Assistance Provider Agreement for Managed Care Plan, Ohio Medical Assistance Provider Agreement for Managed Care Plan
